Important development in the treatment of multiple sclerosis reported

Aug 24, 2009
Important development in the treatment of MS
An MS lesion within human brain tissue, revealing numerous galanin-positive cells (black dots). Photo by David Wynick

A major step forward, with important implications for understanding how to reduce the severity of multiple sclerosis, has been made by scientists at the University of Bristol. The results are published online today in PNAS.

The team found that mice designed to express a large amount of the neuropeptide ‘galanin’ were completely resistant to the MS-like disease, experimental autoimmune encephalomyelitis (EAE). Transgenic mice that contained no galanin at all developed a more severe form of the disease.

Subsequent tests on human brain tissue affected by MS showed galanin to be specifically upregulated in MS lesions and shadow plaques, which are often seen in acute MS.

These important results suggest that galanin could have future therapeutic implications for .

Professor David Wynick who initiated the research and works on the function of galanin in the relief of neuropathic pain said: “It has been known for some time that galanin plays a protective role in both the central and systems; when a nerve is injured levels of galanin increase dramatically in an attempt to limit .

“When I heard that someone had shown galanin was upregulated in Alzheimer’s disease, I decided to investigate if it was also important in MS. To do this I formed a collaboration with Professors David Wraith and Neil Scolding who both work on MS.”

Wraith, who is working on a vaccine for the treatment of multiple sclerosis, investigated the MS-like disease in the various galanin developed in the Wynick lab.

Professor Wraith said: “The results were really remarkable: rarely do you see such a dramatic effect as this. Mice with high levels of galanin just didn’t develop any signs of disease. We have a lot more to do to figure out how this works but the results are extremely promising.”

Wynick then turned to Professor Neil Scolding who studies the use of in the treatment of multiple sclerosis. Scolding provided human brain tissue affected by multiple sclerosis and, as the team predicted, galanin was also shown to be upregulated in this .

Professor Scolding said: “The results of this research are very significant and provide new insights into how the disease might be treated”.

Although these early results are very encouraging there is still a large amount of work to be done before a drug can be developed to help MS sufferers, and it will be at least 10 years before such a drug is on the market.

Professor Wynick’s spin-out company, NeuroTargets, owns the intellectual property relating to this work and it will be seeking the substantial funding needed to advance these findings.

More information: A role for galanin in human and experimental inflammatory demyelination by David C. Wraith, Robert Pope, Helmut Butzkueven, Heidi Holderd, Penny Vanderplank, Pauline Lowrey, Michael J. Day, Andrew L. Gundlach, Trevor J. Kilpatrick, Neil Scolding and David Wynick. PNAS online, 24 August 2009.

Provided by University of Bristol (news : web)

Explore further: First successful vaccination against 'mad cow'-like wasting disease in deer

add to favorites email to friend print save as pdf

Related Stories

Caffeine prevents multiple sclerosis-like disease in mice

Apr 07, 2008

Mice given caffeine equivalent to a human drinking six to eight cups of coffee a day were protected from developing experimental autoimmune encephalomyelitis (EAE), the animal model for the human disease Multiple Sclerosis ...

New drug protects nerve cells from damage in mice

Mar 14, 2008

Multiple sclerosis (MS) is a chronic inflammatory disease of the brain and spinal cord. Individuals with MS develop progressive neurological disability, and this is thought to be caused by degradation of the nerve cells. ...

Study of bone marrow stem cells in multiple sclerosis

Sep 26, 2007

A new pilot clinical trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis has started at Frenchay Hospital. The aim of the trial, conducted by the University of Bristol and North ...

Best treatment for MS may depend on disease subtype

Jul 01, 2008

Animal studies by University of Michigan scientists suggest that people who experience the same clinical signs of multiple sclerosis (MS) may have different forms of the disease that require different kinds of treatment.

Recommended for you

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Nartoon
1 / 5 (1) Aug 25, 2009
Is this a preventative, as shown in the mice experiments, or is it a cure after MS has developed. MS goes though long times of regression, so I assume once the first symptoms appear is the ideal time to strike, but what about those already in later stages?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.